Analgesic Effects of Combined Nalbuphine-bupivacaine Versus Dexamethasone-bupivacaine in Pericaps… (NCT06972654) | Clinical Trial Compass
CompletedNot Applicable
Analgesic Effects of Combined Nalbuphine-bupivacaine Versus Dexamethasone-bupivacaine in Pericapsular Nerve Group Block (PENG) After Hip Surgeries: A Randomized Clinical Study
Egypt102 participantsStarted 2025-04-01
Plain-language summary
The aim of the study to Evaluate the efficacy of nalbuphine-bupivacaine vs dexamethasone-bupivacaine in ultrasound guided pericapsular nerve group (PENG) block for improving pain management, reducing opioid consumption, and enhancing the overall analgesic effect in patients undergoing hip surgeries.
Who can participate
Age range21 Years – 75 Years
SexALL
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Inclusion criteria:
* Patients acceptance.
* Age: Adults aged 21-75 years old.
* BMI: 25-30 kg/m2
* Sex: both sexes (males or females).
* Patients undergoing unilateral hip surgery under spinal anesthesia.
* ASA (American Society of Anesthesiologists) physical status classification I, II and â…˘..
\*Exclusion criteria:
* Patients with contraindications to regional anesthesia (e.g. local or systemic infections, or severe neurological or muscular disorders or patient on anticoagulant).
* Allergy to study drugs: bupivacaine or nalbuphine or dexamethasone
* Patients with severe cardiovascular, respiratory, renal, or hepatic conditions, uncontrolled diabetes diseases, or those undergoing chronic opioid therapy.
* Psychiatric disorders that hinder informed consent or study participation.
* history of neurological diseases or conditions that would affect the efficacy of nerve blocks (e.g., neuropathy, spinal cord injury, or history of severe muscle weakness).